Renvela: new phosphate binder formulation

Renvela is available in the same 800mg tablet presentation as Renagel, as well as 2.4g sachets of powder for oral suspension.
Renvela is available in the same 800mg tablet presentation as Renagel, as well as 2.4g sachets of powder for oral suspension.

Genzyme has launched Renvela, a new version of the phosphate binder sevelamer.

Sevelamer is a crosslinked polymer that binds phosphate molecules in the intestine.

Renvela contains the carbonate salt of the drug, whereas the existing formulation Renagel contains sevelamer hydrochloride.

Both are licensed for the treatment of hyperphosphataemia in patients on dialysis. Renvela is also licensed for use in patients with chronic kidney disease not on dialysis.

Two randomised controlled trials in the haemodialysis setting (one in 79 patients, the other in 31 patients) demonstrated the equivalence of sevelamer carbonate tablets and powder, respectively, to sevelamer hydrochloride tablets for serum phosphate control.

View Renvela drug record

Further information: Genzyme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...